BioSphings has developed a portfolio of drug candidates which target pathways of the lipid metabolism.

These drug candidates interfere specifically with the activity of phospholipases.

Phospholipases are enzymes which play a major role in many signal transduction events, for example in activation mechanism of persisting viruses or in programmed cell death.

The drug candidate LMV-601, which is licensed to Lumavita AG, is applicable for the treatment of diseases induced by widely prevailing viruses such as HSV, VZV and HPV.

The drug candidate Aponidin induces cell death of autoreactive immune cells and of certain tumor cells.

For more information about our drug portfolio and about potential licensing opportunities, please contact us.

© BioSphings AG 2011